Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

ITOS – ITeos Therapeutics Inc

iTeos Therapeutics, Inc.
ITOS
$10.09
Name : iTeos Therapeutics, Inc.
Sector : Healthcare
Industry: Biotechnology
Mark. Cap: $445,687,424.00
EPSttm : -3.05
finviz dynamic chart for ITOS
iTeos Therapeutics, Inc.
$10.09
0.49%
$0.05

Float Short %

8.56

Margin Of Safety %

Put/Call OI Ratio

0.92

EPS Next Q Diff

0.01

EPS Last/This Y

-0.02

EPS This/Next Y

0.65

Price

10.09

Target Price

12.71

Analyst Recom

3

Performance Q

34.53

Relative Volume

0.93

Beta

1.49

Ticker: ITOS




21 items of 1

DateSymbolLastP/C OIP/C VolTotal OI
2025-07-04ITOS10.180.830.2623484
2025-07-07ITOS10.090.831.4223563
2025-07-08ITOS10.120.840.4423797
2025-07-09ITOS10.230.842.6523913
2025-07-10ITOS10.220.851.0624349
2025-07-11ITOS10.270.914.9225174
2025-07-14ITOS10.340.980.9526249
2025-07-15ITOS10.30.970.6029893
2025-07-16ITOS10.280.9782.5029920
2025-07-17ITOS10.260.980.5130047
2025-07-18ITOS10.270.990.1230086
2025-07-21ITOS10.140.770.7121825
2025-07-22ITOS10.10.802.0923974
2025-07-23ITOS10.110.9073.1524853
2025-07-24ITOS10.130.962.8725671
2025-07-25ITOS10.181.0310.8826374
2025-07-28ITOS10.121.050.0026698
2025-07-29ITOS10.120.967.8425593
2025-07-30ITOS10.120.970.0025916
2025-07-31ITOS10.140.970.1625987
2025-08-01ITOS10.10.9220.1426940
DateSymbolLastP/C OIP/C VolTotal OI
21 items Current Page1 of 1




21 items of 1

DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
2025-07-04ITOS10.18-342.4- -2.97
2025-07-07ITOS10.08-342.4- -2.97
2025-07-08ITOS10.12-342.4- -2.97
2025-07-09ITOS10.23-342.4- -2.97
2025-07-10ITOS10.21-342.4- -2.97
2025-07-11ITOS10.29-342.4- -2.97
2025-07-14ITOS10.35-342.4- -2.97
2025-07-15ITOS10.31-342.4- -2.97
2025-07-16ITOS10.28-342.4- -2.97
2025-07-17ITOS10.26-342.4- -2.97
2025-07-18ITOS10.27-342.4- -2.97
2025-07-21ITOS10.14-342.4- -2.97
2025-07-22ITOS10.11-342.4- -2.97
2025-07-23ITOS10.13-342.4- -2.97
2025-07-24ITOS10.15-342.4- -2.97
2025-07-25ITOS10.17-342.4- -3.34
2025-07-28ITOS10.12-358.3- -3.34
2025-07-29ITOS10.11-358.3- -3.34
2025-07-30ITOS10.12-358.3- -3.34
2025-07-31ITOS10.14-358.3- -3.34
2025-08-01ITOS10.09-358.3- -3.34
DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
21 items Current Page1 of 1




21 items of 1

DateTickerInsider TransactionsInstitutional TransactionsFloat Short
2025-07-04ITOS032.207.53
2025-07-07ITOS032.217.53
2025-07-08ITOS032.217.53
2025-07-09ITOS032.217.53
2025-07-10ITOS032.217.53
2025-07-11ITOS032.217.90
2025-07-14ITOS032.327.90
2025-07-15ITOS032.327.90
2025-07-16ITOS032.327.90
2025-07-17ITOS032.327.90
2025-07-18ITOS032.327.90
2025-07-21ITOS032.067.90
2025-07-22ITOS032.067.90
2025-07-23ITOS032.067.90
2025-07-24ITOS032.067.90
2025-07-25ITOS032.068.56
2025-07-28ITOS023.588.56
2025-07-29ITOS023.588.56
2025-07-30ITOS023.588.56
2025-07-31ITOS023.588.56
2025-08-01ITOS023.588.56
DateTickerInsider TransactionsInstitutional TransactionsFloat Short
21 items Current Page1 of 1

Last Quarter Act. EPS

-0.8

Avg. EPS Est. Current Quarter

-0.8

Avg. EPS Est. Next Quarter

-0.79

Insider Transactions

Institutional Transactions

23.58

Beta

1.49

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

23

Growth Score

22

Sentiment Score

40

Actual DrawDown %

80.8

Max Drawdown 5-Year %

-89.5

Target Price

12.71

P/E

Forward P/E

PEG

P/S

11.03

P/B

0.69

P/Free Cash Flow

EPS

-3.23

Average EPS Est. Cur. Y​

-3.34

EPS Next Y. (Est.)

-2.68

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

-373.75

Relative Volume

0.93

Return on Equity vs Sector %

-47

Return on Equity vs Industry %

-28.3

EPS 1 7Days Diff

EPS 1 30Days Diff

-0.37

EBIT Estimation

iTeos Therapeutics, Inc.
Sector: Healthcare
Industry: Biotechnology
Employees: 173
iTeos Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of immuno-oncology therapeutics for patients with cancer. The company's lead antibody product candidate, belrestotug, an antagonist of T-cell immunoreceptor with Ig and ITIM domains (TIGIT), as well as engages the Fc gamma receptor to activate dendritic cells, natural killer cells, T lymphocytes, and macrophages and to promote the release of cytotoxic granules and antibody-dependent cellular cytotoxicity activity. Its product pipeline also includes inupadenant, a next-generation A2AR antagonist program; EOS-984, a small molecule targeting equilibrative nucleoside transporter 1 (ENT1) to reverse immunosuppression and restore T cell proliferation in the tumor microenvironment; and EOS-215, a monoclonal antibody which antagonizes triggering receptor expressed on triggering receptor expressed on myeloid cells 2. Iteos Therapeutics, Inc. was founded in 2011 and is headquartered in Watertown, Massachusetts.
stock quote shares ITOS – ITeos Therapeutics Inc Stock Price stock today
news today ITOS – ITeos Therapeutics Inc stock forecast ,stock prediction 2023 2024 2025
marketwatch ITOS – ITeos Therapeutics Inc yahoo finance google finance
stock history ITOS – ITeos Therapeutics Inc invest stock market
stock prices ITOS premarket after hours
ticker ITOS fair value insiders trading